Skip to content

Multi-center prospective and observational study on efficacy and safety of Guipi capsule in treating insomnia with deficiency of heart and spleen

Multi-center prospective and observational study on efficacy and safety of Guipi capsule in treating insomnia with deficiency of heart and spleen

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000590
Enrollment
Unknown
Registered
2025-03-25
Start date
2025-01-09
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia with deficiency of heart and spleen

Interventions

research group:This study does not limit the patients' treatment regimen all enrolled patients were treated with Guipi capsule alone or in replacement or combination with current treatment regimen.0.3

Sponsors

Zhongda Hospital Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for insomnia in the International Classification of Sleep Disorders (3rd edition) (ICSD-3); (2) Meet the relevant diagnostic criteria in the "Clinical Practice Guidelines for Insomnia in Chinese Medicine" and belong to the syndrome of deficiency of the heart and spleen; (3) 18 years old = age = 75 years old gender is not limited; (4) Patients who agree to accept the use of Guisheng Capsules alone or in replacement or combination with the current treatment regimen; (5) Good compliance voluntary participation in the study and signing of informed consent.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Patients with external fever and internal heat manifestations such as thirst yellowish urine and constipation; (3) Subjects who are unable to understand and complete the content of the relevant scale due to language visual or intellectual disabilities; (4) Subjects with comorbid serious mental illness (e.g. schizophrenia mood disorder) serious liver and kidney function impairment; (5) Subjects with active malignant neoplastic disease; (6) Subjects who are allergic to any component of the drug in this trial; (7) Participation in any other clinical trial currently or within the past 1 month; (8) Subjects who have used a reversionary product in the 1 month prior to enrollment; (9) Unsuitable for participation in this study as judged by the investigator.

Design outcomes

Primary

MeasureTime frame
PSQI;

Secondary

MeasureTime frame
PSG;WHOQOL-BREF;PSQI;PHQ-9;ISI;Chinese Medicine Points Scale;

Countries

China

Contacts

Public ContactYonggui Yuan

Zhongda Hospital Southeast University

yygylh2000@sina.com+86 139 1393 9082

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026